These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 9784520)
1. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Thakker M; Park JS; Carey V; Lee JC Infect Immun; 1998 Nov; 66(11):5183-9. PubMed ID: 9784520 [TBL] [Abstract][Full Text] [Related]
2. Overproduction of type 8 capsular polysaccharide augments Staphylococcus aureus virulence. Luong TT; Lee CY Infect Immun; 2002 Jul; 70(7):3389-95. PubMed ID: 12065477 [TBL] [Abstract][Full Text] [Related]
3. Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo. Liu B; Park S; Thompson CD; Li X; Lee JC Virulence; 2017 Aug; 8(6):859-874. PubMed ID: 27936346 [TBL] [Abstract][Full Text] [Related]
4. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Watts A; Ke D; Wang Q; Pillay A; Nicholson-Weller A; Lee JC Infect Immun; 2005 Jun; 73(6):3502-11. PubMed ID: 15908379 [TBL] [Abstract][Full Text] [Related]
5. Phagocytosis of mastitis isolates of Staphylococcus aureus and expression of type 5 capsular polysaccharide are influenced by growth in the presence of milk. Sutra L; Rainard P; Poutrel B J Clin Microbiol; 1990 Oct; 28(10):2253-8. PubMed ID: 2229349 [TBL] [Abstract][Full Text] [Related]
6. Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Lee JC; Takeda S; Livolsi PJ; Paoletti LC Infect Immun; 1993 May; 61(5):1853-8. PubMed ID: 8478074 [TBL] [Abstract][Full Text] [Related]
7. Staphylococcus aureus capsular polysaccharide types 5 and 8 reduce killing by bovine neutrophils in vitro. Kampen AH; Tollersrud T; Lund A Infect Immun; 2005 Mar; 73(3):1578-83. PubMed ID: 15731056 [TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Lee JC; Park JS; Shepherd SE; Carey V; Fattom A Infect Immun; 1997 Oct; 65(10):4146-51. PubMed ID: 9317020 [TBL] [Abstract][Full Text] [Related]
9. Identification of a gene essential for O-acetylation of the Staphylococcus aureus type 5 capsular polysaccharide. Bhasin N; Albus A; Michon F; Livolsi PJ; Park JS; Lee JC Mol Microbiol; 1998 Jan; 27(1):9-21. PubMed ID: 9466251 [TBL] [Abstract][Full Text] [Related]
10. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Nanra JS; Buitrago SM; Crawford S; Ng J; Fink PS; Hawkins J; Scully IL; McNeil LK; Aste-Amézaga JM; Cooper D; Jansen KU; Anderson AS Hum Vaccin Immunother; 2013 Mar; 9(3):480-7. PubMed ID: 23249887 [TBL] [Abstract][Full Text] [Related]
11. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Cerca N; Jefferson KK; Maira-Litrán T; Pier DB; Kelly-Quintos C; Goldmann DA; Azeredo J; Pier GB Infect Immun; 2007 Jul; 75(7):3406-13. PubMed ID: 17470540 [TBL] [Abstract][Full Text] [Related]
12. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Cunnion KM; Lee JC; Frank MM Infect Immun; 2001 Nov; 69(11):6796-803. PubMed ID: 11598052 [TBL] [Abstract][Full Text] [Related]
13. Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Kropec A; Maira-Litran T; Jefferson KK; Grout M; Cramton SE; Götz F; Goldmann DA; Pier GB Infect Immun; 2005 Oct; 73(10):6868-76. PubMed ID: 16177366 [TBL] [Abstract][Full Text] [Related]
14. The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis. Kuipers A; Stapels DAC; Weerwind LT; Ko YP; Ruyken M; Lee JC; van Kessel KPM; Rooijakkers SHM Microbiology (Reading); 2016 Jul; 162(7):1185-1194. PubMed ID: 27112346 [TBL] [Abstract][Full Text] [Related]
15. Milk complement and the opsonophagocytosis and killing of Staphylococcus aureus mastitis isolates by bovine neutrophils. Barrio MB; Rainard P; Poutrel B Microb Pathog; 2003 Jan; 34(1):1-9. PubMed ID: 12620379 [TBL] [Abstract][Full Text] [Related]
16. Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Albus A; Arbeit RD; Lee JC Infect Immun; 1991 Mar; 59(3):1008-14. PubMed ID: 1847696 [TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States. Mohamed N; Timofeyeva Y; Jamrozy D; Rojas E; Hao L; Silmon de Monerri NC; Hawkins J; Singh G; Cai B; Liberator P; Sebastian S; Donald RGK; Scully IL; Jones CH; Creech CB; Thomsen I; Parkhill J; Peacock SJ; Jansen KU; Holden MTG; Anderson AS PLoS One; 2019; 14(1):e0208356. PubMed ID: 30641545 [TBL] [Abstract][Full Text] [Related]
18. Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease. Tkaczyk C; Hamilton MM; Sadowska A; Shi Y; Chang CS; Chowdhury P; Buonapane R; Xiao X; Warrener P; Mediavilla J; Kreiswirth B; Suzich J; Stover CK; Sellman BR mBio; 2016 Jun; 7(3):. PubMed ID: 27353753 [TBL] [Abstract][Full Text] [Related]
19. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Fattom AI; Sarwar J; Ortiz A; Naso R Infect Immun; 1996 May; 64(5):1659-65. PubMed ID: 8613375 [TBL] [Abstract][Full Text] [Related]
20. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Xu S; Arbeit RD; Lee JC Infect Immun; 1992 Apr; 60(4):1358-62. PubMed ID: 1548061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]